The Amylin Mystery And Bydureon Sales - Forbes

Links shared publicly online about this topic.

0
total visits

The Amylin Mystery And Bydureon Sales - Forbes

As pundits continue to ponder the unanswered questions surrounding Amylin Pharmaceuticals and its rejection of a bid by Bristol-Myers Squibb – did the big drugmaker really make a bid? if so, when? and why did Amylin say no? – a key issue has been the value of the Bydureon diabetes drug.

View full resource at forbes.com

Tags: